Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes

Journal of Nuclear Medicine

Volumn 42, Issue 9, 2001, Pages 1412-1417

  Zhuang, H ^a   Pourdehnad, M ^a   Lambright, E S ^a   Yamamoto, A J ^a   Lanuti, M ^a   Li, P ^a   Mozley, P D ^a   Rossman, M D ^a   Albelda, S M ^a   Alavi, A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dual time point imaging; FDG; Inflammation; Malignancy; PET; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT;

AGED; ANIMALS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; MALE; MICE; MIDDLE AGED; NEOPLASMS; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR CELLS, CULTURED;

EID: 0034850172     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
2. FDG accumulation and tumor biology
3. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes
4. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues
5. Benign causes of 18-FDG uptake on whole body imaging
6. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: Preliminary results
7. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging
8. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients
9. A new procedure to overlay diluted blood on Ficoll-Hypaque gradients
10. Myeloma affects both the growth and function of human osteoblast-like cells
11. Establishment of a murine model of malignant mesothelioma
12. Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines
13. Selection of successive tumour lines for metastasis
14. Absence of HeLa cell contamination in 169 cell lines derived from human tumors
15. Culture media for human cells: RPMI 1630, RPMI 1634, RPMI 1640 and GEM 1717
16. Three-dimensional imaging characteristics of the HEAD PENN-PET scanner
17. Standardized uptake values of FDG: Body surface area correction is preferable to body weight correction
18. 137Cs source
19. Whole-body positron emission tomography for oncology imaging using singles transmission scanning with segmentation and ordered subsets expectation maximization (OS-EM) reconstruction
20. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning
21. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images
22. Untreated primary lung and breast cancers: Correlation between F-18 FDG kinetic rate constants and findings of in vitro studies
23. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine
24. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: An unsolved problem
25. Can the standardized uptake value characterize primary brain tumors on FDG-PET?
26. Standardized uptake value as an unreliable index of renal disease on FDG-PET imaging
27. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue
28. The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification?
29. 18FDG uptake in soft tissue masses
30. Technetium-99m(V)-DMSA and thallium-201 in brain tumor imaging: Correlation with histology and malignant grade
31. Clinical application of T1-201 SPECT imaging of brain tumors
32. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers
33. 18F]2-deoxy-2-fluoro-D-glucose
34. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxy-glucose retention in murine tumor models
35. Partial purification from human mononuclear cells and placental plasma membranes of an insulin mediator which stimulates pyruvate dehydrogenase and suppresses glucose-6-phosphatase
36. FDG-PET in oncology: There's more to it than looking at pictures
37. Determination of 2-fluoro-2-deoxy-D-glucose uptake and ATP level for evaluating drug effects in neoplastic-cells
38. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells
39. Dual time point fluorine-18 fluorodeoxy-glucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck
40. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer